As CSL embarks on a restructuring drive to save more than $500 million annually over the next three years, the Australian company’s workforce reduction plans have reached one of its subsidiaries in ...
Positive safety and pharmacokinetic data lay foundation for phase 2 study in 2026 Herantis Pharma has announced positive topline results from its phase 1b trial of HER-096 in people living with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback